Synthesis route for IPED2015 Selected
Initiator Pharma has over the recent months developed a robust and efficient drug substance synthesis route together with CRO partner, Syngene, under the supervision of Initiator Pharma’s CTO Dan Peters and CDO Mikael Thomsen. Comment from the CTO‘We have identified, selected and optimized the synthesis route for IPED2015 and are now focusing on the scale-up of the drug substance production.’ The optimal synthesis route (subject to scale, cost, sustainability, time and quality) has now been identified and selected, and the IPED2015 drug is currently in the process of up-scaling to